Stoke Therapeutics Inc is a biotechnology company focused on developing innovative therapies to treat genetic diseases by harnessing the power of messenger RNA (mRNA) biology
The company is dedicated to addressing the underlying causes of diseases by enhancing the production of proteins through its proprietary platform, which aims to restore the normal function of genes that are dysfunctional due to genetic mutations. By prioritizing precision medicine, Stoke Therapeutics works towards delivering transformative treatments that can improve the quality of life for patients suffering from various neurological disorders and other serious conditions.
Biogen and Stoke partner on zorevunersen for Dravet syndrome, with a Phase 3 trial starting in 2025. Stoke gets $165 million upfront and milestone payments.
After the market close on Tuesday, Stoke Therapeutics announced a proposed underwritten public offering of up to $75 million of its common stock. The company also intends to grant the underwriters a 30-day window to purchase up to an additional 15% of the shares in the public offering.
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 80 points on Tuesday. The Dow traded up 0.21% to 39,397.20 while the NASDAQ rose 0.23% to 16,421.62. The S&P 500 also rose, gaining, 0.17% to 5,227.03.
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 100 points on Tuesday. The Dow traded up 0.25% to 39,413.30 while the NASDAQ rose 0.27% to 16,448.55. The S&P 500 also rose, gaining, 0.27% to 5,232.36.
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Tuesday. The Dow traded up 0.08% to 39,346.40 while the NASDAQ rose 0.39% to 16,448.92. The S&P 500 also fell, dropping, 0.23% to 5,230.19.
New data from Stoke Therapeutics' STK-001 studies reveal significant reductions in seizures and cognitive improvements in children with Dravet syndrome. STK-001 demonstrates promise as a well-tolerated treatment option, even for highly refractory patients.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase 1/2a data supporting the potential for STK-001
